Bharat Biotech Vaccine Doses Touch 1 Billion

Hyderabad, India, February 3, 2010: Bharat Biotech announced today that it just delivered its 1 billionth vaccine dose. This accomplishment demonstrates the determination and dedication of Bharat Biotech in providing health care solutions to millions of people in India and the developing world. Bharat Biotech is a global manufacturer of vaccines to protect against rabies, polio, hepatitis-B, typhoid, diphtheria, pertussius, tetanus, haemophilus influenza B and other diseases.

“This is a symbolic moment for Bharat Biotech, since it documents our past performance while laying the foundation for our future growth” Dr. Krishna M. Ella, Chairman and Managing Director said, Commenting on this milestone event, Dr. Ella further added; “While the manufacture and sale of a billion doses gives us a great sense of pride and accomplishment, we at Bharat Biotech realize that life saving vaccines are still unavailable to millions of people and there is a lot more work to be done. We are truly committed to research and development of innovative vaccines to address global infectious diseases”

Bharat Biotech has cultivated a strong culture of innovation with focus on infectious diseases of the developing world.

Bharat Biotech has novel vaccine development projects such as rotavirus vaccine, typhoid conjugate vaccine, malaria vaccine, Japanese encephalitis vaccine, chikungunya vaccine, pandemic/seasonal influenza vaccine etc.

The Future growth strategy at Bharat Biotech is well laid out with a combination of high volume WHO prequalified vaccines and innovative novel vaccines catering to the needs of developing world populations.

Going forward Bharat Biotech intends to further strengthen its clinical research activities through a series of investments into safety and efficacy clinical trials for its innovative vaccines and therapeutics. The company intends to inject 30% of its revenues in R& D and Clinical Research.

It has taken Bharat Biotech ~ 10 years to reach its first billion doses, the 2nd billion doses would reached in less than 5 years” Dr. Ella said.

About Bharat Biotech International Limited

Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is one of the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA). Bharat Biotech is also a WHO prequalified manufacturer of Hepatitis-B vaccines for supply to UNICEF and global procurement agencies. Bharat Biotech is one of the largest manufacturer of anti-rabies vaccines in India. INDIRAB® is a market leader in India and several countries globally.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.

Back to news